Pharmacokinetics and drug interactions of eslicarbazepine acetate

Epilepsia

Volumn 53, Issue 6, 2012, Pages 935-946

  Bialer, Meir ^a,b   Soares Da Silva, Patricio ^c,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; Drug interactions; Eslicarbazepine; Eslicarbazepine acetate; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLOBAZAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DIAZEPAM; DIGOXIN; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; LAMOTRIGINE; LICARBAZEPINE; METFORMIN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SIMVASTATIN; STEDESA; TOLBUTAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; EPILEPSY; HUMAN; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; NEURAL CREST; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ANIMALS; ANTICONVULSANTS; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPILEPSY; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER;

EID: 84861792459     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03519.x     Document Type: Review

References (55)

1. Almeida L, Soares-da-Silva P,. (2003) Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R&D 4: 269-284.
2. Almeida L, Soares-da-Silva P,. (2004) Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 44: 906-918.
3. Almeida L, Soares-da-Silva P,. (2007) Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 4: 88-96.
4. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P,. (2005) Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 45: 1062-1066.
5. Almeida L, Falcão A, Maia J, Vaz-da-Silva M, Soares E, Soares-da-Silva P,. (2006a) Steady-state pharmacokinetics of once-daily and twice-daily regimens of eslicarbazepine acetate (BIA 2-093) in healthy subjects. AES Proc Epilepsia 47 (Suppl. 4): 154, Abstarct 2.102.
6. Almeida L, Vaz-da-Silva M, Falcão A, Maia J, Soares E, Soares-da-Silva P,. (2006b) Effect of eslicarbazepine acetate (BIA 2-093) on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Proceedings of the 7th European Congress on Epileptology, Helsinki; Abstract Book.
7. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P,. (2008) Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 64: 267-273.
8. Almeida L, Bialer M, Soares-da-Silva P,. (2009) Eslicarabzepine acetate. In, Shorvon S, Perucca E, Engel J, (Eds) The epilepsy treatment of epilepsy. 3rd ed. Wiley-Blackwell, Oxford, pp. 485-498.
9. Almeida L, Nunes T, Sicard E, Rocha J-F, Falcão A, Brunet J-S, Lefevbvre M, Soares-da-Silva P,. (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 121: 257-264.
10. Alves G, Figueiredo I, Falcão A, Castel-Branco M, Caramona M, Soares Da-Silva P,. (2008) Stereoselective disposition of S- and R-licarbazepine in mice. Chirality 20: 796-804.
11. Amidon GL, Lennernas H, Shah VP, Crison JR,. (1995) A theoretical basis for a bioequivalence drug classification; the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
12. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P,. (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 89: 278-285.
13. Bialer M, (2002) Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins Publishers, New York, pp. 459-465.
14. Bialer M,. (2006) New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 15: 637-647.
15. Bialer M, White HS,. (2010) Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 29: 68-83.
16. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61: 1-48.
17. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73: 1-52.
18. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS,. (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83: 1-43.
19. Boxenbaum H, Battle M,. (1995) Effective half-life in clinical pharmacology. Clin Pharmacol 35: 763-766.
20. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P,. (2007) Eslicarbazepine acetate: a double-blind, add-on placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48: 497-503.
21. Elger C, Halas P, Maia J, Almeida L, Soares-da-Silva P,. (2009) Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 50: 454-463.
22. Faigle JW, Menge GP,. (1990) Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int J Clin Psychopharmacol 5: 73-82.
23. Falcão A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P,. (2007) Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 28: 249-256.
24. Falcão A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P,. (2012) Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures. CNS Drugs 26: 79-91.
25. Fattore C, Cipolla G, Gatti G, Limido GL, Strum Y, Bernasconi C, Perucca E,. (1999) Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40: 783-787.
26. Flesch G,. (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24: 185-203.
27. Flesch G, Czendik C, Ehrhart F, Hell F, Lloyd P,. (1999) Pharmacokinetics of the two enantiomers of the monohydroxy derivative of oxcarbazepine in man. Eur J Pharm Sci 8:xxii Abstract 89.
28. Flesch G, Czendlik C, Renard D, Lloyd P,. (2011) Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its two enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dipsosit 39: 1103-1110.
29. Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P,. (2005) Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulations. Drugs R D 6: 253-260.
30. Fortuna A, Sousa J, Alves G, Falcao A, Soares-da-Silva P,. (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397: 1605-1615.
31. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P,. (2009) Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 120: 281-287.
32. Hainzl D, Parada A, Soares-da-Silva P,. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 44: 197-206.
33. Kharidia J, Maier G, Versavel M, Blum D, Maia J, Soares-da-Silva P,. (2010) CSF and plasma pharmacokinetics of eslicarbazepine acetate and oxcarbazepine in healthy subjects. AES Annual Meeting, San Antonio, Abstract.
34. Kwan KC, Bohidar NR, Hwang SS,. (1984) Estimation of an effective half-life. In, Benet LZ, Levy G, Ferraiolo B, (Eds) Pharmacokinetics: a modern view. Plenum Press, New York, pp. 147-162.
35. Lakehal F, Wurden CJ, Kalhorn TF, Levy RH,. (2002) Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 52: 79-82.
36. Loureiro AI, Fernanades-Lopes C, Bonifacio MJ, Wright LC, Soares-da-Silva P,. (2011a) Hepatic UDP-glucuronosyltransferase responsible for eslicarbazepine glucuronidation. Drug Meta Disposit 39: 1486-1494.
37. Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P,. (2011b) Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2611-2618.
38. Maia J, Almeida L, Vaz-da-Silva M, Soares E, Tavares S, Falcão A, Soares-da-Silva P,. (2005) Effect of eslicarbazepine acetate on the steady-state pharmacokinetics of digoxin in healthy subjects. Epilepsia 46: 178-79 (abstract).
39. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, Potgieter MA, Soares-da-Silva P,. (2008) Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 46: 119-130.
40. Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S, Vezzani A,. (2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46: 1613-1619.
41. Mauro VF,. (1993) Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24: 195-202.
42. Nunes T, Minciu I, Almeida L, Magureanu SA, Falcão A, Butoianu N, Soares-da-Silva P,. (2007) Pharmacokinetics of eslicarbazepine acetate in children and adolescents with epilepsy. Proceedings of the 27th International Epilepsy Congress, Singapore 2007; Abstract Book.
43. Nunes T, Sicard E, Almeida L, Falcão A, Rocha J-F, Brunet J-S, Lefevre M, Soares-da-Silva P,. (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 6: 1355-1362.
44. Perucca E, Elger C, Halasz P, Falcao A, Almeida L, Soares-da-Silva P,. (2011) Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 96: 132-139.
45. Rocha J-F, Vaz-da-Silva M, Almeida L, Falcão A, Nune T, Santos A-T, Martins F, Fontes-Ribeiro C, Soares-da-Silva P,. (2009) Effect of eslicarbazepine acetate on the pharmacokinetics a of metformin in healthy subjects. Int J Clin Pharmacol Ther 47: 255-261.
46. Rowland M, Tozer T,. (2010) Clinical pharmacokinetics and pharmacodynamics. 4th ed. Walter Kluwer, Philadelphia, PA, pp. 203-204.
47. Sahin S, Benet LZ,. (2008) The operational multiple-dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25: 2869-2877.
48. 14C-oxcarbazepine in humans. Xenobiotica 8: 769-778.
49. Vaz-da-Silva M, Nunes T, Soares E, Rocha JF, Tavares S, Falcão A, Almeida L, Soares-da-Silva P,. (2005) Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects. Epilepsia 46: 191 (abstract).
50. Vaz-da-Silva M, Costa R, Soares E, Maia J, Falcão A, Almeida L, Soares-da-Silva P,. (2009) Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 23: 509-514.
51. Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nune T, Soares-da-Silva P,. (2010) Effect of eslicarbazepine acetate on steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three stage, open-label, multiple-dose, single-period study. Clin Ther 32: 179-192.
52. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M,. (1999) Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 66: 547-553.
53. Wen Z, Martin DE, Bullock P, Lee KH, Smith PC,. (2007) Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP- glucuronosyltransferases and species differences. Drug Metab Disposit 35: 440-448.
54. Wu C-Y, Benet LZ,. (2005) Predicting drug disposition via application of BCS: Transport/absorption elimination interplay and development of biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
55. Zenser TV, Lakshmi VM, Davis BB,. (1999) Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Disposit 27: 1064-1067.